FIELD: medicine, neurosurgery.
SUBSTANCE: the innovation deals with detecting the availability of immune response to tumor immediately after operation followed by carrying out immunotherapy at positive curative effect. The selection neurooncological patients for immunotherapy should be conducted due to homogenization of tumor fragment in buffer A, treatment with protein A out of Staphilococcus aureus and being monospecific IgG ligand and fluorescein-labelled, then it is important to determine the intensity of antibodies binding at cell surface according to the degree of fluorescent luminosity. Moreover, in case of fluorescent luminosity being above 50% of the surface of the material under testing one should conclude on carrying out immunotherapy for these neurooncological patients.
EFFECT: higher efficiency of selection.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| APPLICATION OF CELL LINE OF 369 ADMEL HUMAN SKIN MELANOMA | 2017 |
|
RU2642265C1 |
| METHOD OF TREATING METASTATIC CANCER USING SENDAI VIRUS | 2017 |
|
RU2662916C1 |
| TLP-BASE IMMUNOGENIC COMPOSITION | 1997 |
|
RU2192274C2 |
| LASER VACCINATION METHOD FOR PATIENTS SUFFERING FROM METASTATIC CANCER TYPE | 2005 |
|
RU2345788C2 |
| METHOD OF TREATING ONCOLOGICAL DISEASES | 2020 |
|
RU2741701C1 |
| METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
| NEW CANCER ANTIGEN FOR EARLY DETECTION OF CANCER, METHOD FOR OBTAINING, ISOLATION AND DETECTION THEREOF | 2020 |
|
RU2818471C2 |
| ANTIGENIC COMPOSITION AND THERAPEUTIC APPLICATION THEREOF FOR PREVENTING AND TREATING ONCOLOGICAL DISEASES, RECOMBINANT PLASMID DNA, PROVIDING SYNTHESIS OF HYBRID PROTEIN, AS WELL AS METHOD OF PRODUCING PROTEIN | 2013 |
|
RU2590701C2 |
| METHOD FOR MALIGNANT TUMOUR DISEASE RECURRENCE PREDICTION | 2015 |
|
RU2620306C2 |
